Cereno Scientific has received fast track designation from the U.S. Food and Drug Administration (FDA) for CS1, its therapy candidate for pulmonary arterial hypertension (PAH). “We are very pleased to have achieved Fast Track designation for CS1, which both validates the strength of our CS1 program and supports our mission to bring pioneering treatments to […] The post FDA grants fast track status to CS1, Cereno’s therapy candidate for PAH appeared first on Pulmonary Hypertension News.
